TY  - JOUR
AU  - Giné, Eva
AU  - de la Cruz, Fátima
AU  - Jiménez Ubieto, Ana
AU  - López Jimenez, Javier
AU  - Martín García-Sancho, Alejandro
AU  - Terol, M José
AU  - González Barca, Eva
AU  - Casanova, María
AU  - de la Fuente, Adolfo
AU  - Marín-Niebla, Ana
AU  - Muntañola, Ana
AU  - González-López, Tomás José
AU  - Aymerich, Marta
AU  - Setoain, Xavier
AU  - Cortés-Romera, Montserrat
AU  - Rotger, Amanda
AU  - Rodríguez, Sonia
AU  - Medina Herrera, Alejandro
AU  - García Sanz, Ramón
AU  - Nadeu, Ferran
AU  - Beà, Silvia
AU  - Campo, Elías
AU  - López-Guillermo, Armando
PY  - 2022
DO  - 10.1200/JCO.21.02321
UR  - http://hdl.handle.net/10668/20388
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant...
LA  - en
KW  - Adenine
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Humans
KW  - Lymphoma, Mantle-Cell
KW  - Male
KW  - Neoplasm, Residual
KW  - Piperidines
KW  - Rituximab
TI  - Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
TY  - research article
VL  - 40
ER  -